Nemolizumab
Monoclonal antibody
- D11AH12 (WHO)
- US: ℞-only
- 1476039-58-3
- DB15252
- none
- GN465U8B72
- D11080
Nemolizumab, sold under the brand name Nemluvio, is a medication for the treatment of prurigo nodularis.[1] It is a monoclonal antibody that blocks the interleukin-31 receptor A.
Nemolizumab was invented by Chugai, who sold an exclusive license for the drug's development and worldwide marketing (except Japan and Taiwan) to Galderma in 2016.[2]
Nemolizumab was approved for medical use in the United States in August 2024.[3]
Medical uses
Nemolizumab is indicated for the treatment of adults with prurigo nodularis.
Society and culture
Names
Nemolizumab is the international nonproprietary name.[4]
References
- ^ Spreitzer H (27 March 2017). "Neue Wirkstoffe - Nemolizumab". Österreichische Apothekerzeitung (in German) (7/2017).
- ^ "Chugai grants exclusive global license for development and marketing of nemolizumab to Galderma". Pharmabiz.com. 22 July 2016.
- ^ "Galderma Receives U.S. FDA Approval for Nemluvio (nemolizumab) for Adult Patients Living With Prurigo Nodularis" (Press release). Galderma. 13 August 2024. Retrieved 14 August 2024 – via Business Wire.
- ^ World Health Organization (2015). "International nonproprietary names for pharmaceutical substances (INN): recommended INN: list 74". WHO Drug Information. 29 (3). hdl:10665/331070.
Further reading
- Kwatra SG, Yosipovitch G, Legat FJ, Reich A, Paul C, Simon D, et al. (October 2023). "Phase 3 Trial of Nemolizumab in Patients with Prurigo Nodularis". The New England Journal of Medicine. 389 (17): 1579–1589. doi:10.1056/NEJMoa2301333. PMID 37888917.
External links
- Clinical trial number NCT04501666 for "Study to Assess the Efficacy and Safety of Nemolizumab (CD14152) in Participants With Prurigo Nodularis (PN)" at ClinicalTrials.gov
- Clinical trial number NCT04501679 for "A Study to Assess the Efficacy and Safety of Nemolizumab (CD14152) in Participants With Prurigo Nodularis (PN)" at ClinicalTrials.gov
- v
- t
- e
Other dermatological preparations (D11)
- Abrocitinib
- Aminobenzoate potassium
- Androgens (e.g., testosterone)
- Brimonidine
- Caffeine
- Calcium gluconate
- Collagen
- Crisaborole
- Cromoglicic acid
- Deoxycholic acid
- Diclofenac
- Dupilumab
- Estrogens (e.g., estradiol)
- Glycopyrronium tosylate
- Hyaluronic acid
- Hydrogen peroxide
- Ivermectin
- Magnesium sulfate
- Metandienone
- Nemolizumab
- Oxymetazoline
- Pregnenolone acetate
- Progestogens (e.g., progesterone)
- Povidone-iodine
- Tiratricol
- Tralokinumab
Portal:
Medicine
 | This dermatologic drug article is a stub. You can help Wikipedia by expanding it. |
- v
- t
- e
 | This monoclonal antibody–related article is a stub. You can help Wikipedia by expanding it. |
- v
- t
- e
